Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Erin Honan"'
Autor:
Melissa K Accordino, Shing Lee, Cheng-Shiun Leu, Meghna S Trivedi, Katherine D Crew, Kevin M Kalinsky, Rohit Rajhunathan, Alessandra Taboada, Lauren Franks, Erin Honan, Erik Harden, Cynthia Law, Dawn L Hershman
Publikováno v:
Cancer Research. 82:P4-11
Background: Taxane-induced peripheral neuropathy (TIPN) is one of the most common and debilitating adverse effects of taxane therapy for early-stage breast cancer (ESBC). TIPN is difficult to treat, and there are no known effective prevention strateg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10f3faf5ffe1eb8fbe513d3384570c29
https://doi.org/10.1158/1538-7445.sabcs21-p4-11-04
https://doi.org/10.1158/1538-7445.sabcs21-p4-11-04
Autor:
Melissa K Accordino, Sophie Ulene, Erin Honan, Meghna S Trivedi, Katherine D Crew, Erik Harden, Cynthia Law, Dawn L Hershman
Publikováno v:
Cancer Research. 82:P4-11
Introduction: Low medication adherence is associated with worse outcomes among patients with breast cancer (BC). Retrospective studies have shown decreased survival in patients with BC who are non-adherent to endocrine therapy, but less is known abou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb01e004ffe3a72c673b3f42210659e0
https://doi.org/10.1158/1538-7445.sabcs21-p4-11-16
https://doi.org/10.1158/1538-7445.sabcs21-p4-11-16
Autor:
Melissa K Accordino, John H Spivack, Sophie Ulene, Erin Honan, Meghna S Trivedi, Katherine D Crew, Erik Harden, Cynthia Law, Dawn L Hershman
Publikováno v:
Cancer Research. 82:P4-11
Background: There are a growing number of breast cancer (BC) survivors who are at risk for short and long-term treatment-related toxicities. BC survivors may be at higher risk of developing diabetes mellitus (DM), and chemotherapy may potentiate this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7f9514438d6fc898e4453f189433cb6
https://doi.org/10.1158/1538-7445.sabcs21-p4-11-33
https://doi.org/10.1158/1538-7445.sabcs21-p4-11-33
Autor:
Erin Honan, Melissa K. Accordino, Ruby Wu, Kathleen Fenn, Tizita Z. Zeleke, Kevin Kalinsky, Cody Chiuzan, Qingfei Pan, Dawn L. Hershman, Jose Silva, Jiyang Yu, Matthew Maurer, Meghna S. Trivedi, Katherin D Crew, Maika Onishi, Sean A. Kelly
Publikováno v:
Cancer Research. 80:P1-19
Background:HDAC6, a cytoplasmic histone deacetylase, impacts cell viability by influencing protein metabolism, microtubule dynamics, and chaperone function. ACY-1215 is an orally active, selective HDAC6 inhibitor. Preclinical studies have demonstrate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1bc3db3a63fee6cdfca548887c81466
https://doi.org/10.1158/1538-7445.sabcs19-p1-19-27
https://doi.org/10.1158/1538-7445.sabcs19-p1-19-27
Autor:
Tizita Z. Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J. Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S. Trivedi, Melissa Accordino, Katherine D. Crew, Dawn L. Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin Kalinsky, Jiyang Yu, Jose Silva
Publikováno v:
Nature cancer.
Inhibiting individual histone deacetylase (HDAC) is emerging as well-tolerated anticancer strategy compared with pan-HDAC inhibitors. Through preclinical studies, we demonstrated that the sensitivity to the leading HDAC6 inhibitor (HDAC6i) ricolinsta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4bb501f66ef195b4fea1214651717ba
https://pubmed.ncbi.nlm.nih.gov/36585452
https://pubmed.ncbi.nlm.nih.gov/36585452
Autor:
Tizita Z. Zeleke, Matthew Maurer, Meghna S. Trivedi, Ruby Wu, Katherine D. Crew, Mariano J. Alvarez, Pei Ling Chia, Sean A. Kelly, Qingfei Pan, Dawn L. Hershman, Min Yang, Andrea Califano, Jiyang Yu, Partha Mukhopadhyay, Melissa Kate Accordino, Maika Onishi, Cody Chiuzan, Erin Honan, Kathleen Fenn, Jose Silva, Simon Jones, Kevin Kalinsky
Publikováno v:
Cancer Research. 81:645-645
Despite the anticancer activity of pan-histone deacetylase (HDAC) inhibitors, their clinical use has been limited due to toxicity. However, the development of more specific inhibitors that selectively inhibit individual HDACs is emerging as a novel a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49f440092b90d67f34cbca89e882bc5e
https://doi.org/10.1158/1538-7445.am2021-645
https://doi.org/10.1158/1538-7445.am2021-645